Aesthetic product manufacturer BioScience GmbH has launched Hyaprof, a new injectable line which combines monodensified and polydensified dermal fillers.
Following positive phase 2 results from its ready-to-use liquid formulation botulinum toxin, global pharmaceutical company Galderma has received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
Medical aesthetic company Evolus Inc has announced that the European Commission (EC) has approved the marketing of Nuceiva prabotulinumtoxinA (branded Jeuveau in the US and known in other markets as Nabota).
On June 17, more than 250 medical professionals tuned in to the second webinar hosted by Aesthetics and supported by Galderma UK.
US-based medical aesthetic company Evolus Inc has begun a consumer campaign in the US called ‘#NEWTOX NOW’ in the hope to encourage patients to use its botulinum toxin.
On May 14, pharmaceutical company Galderma (UK) Limited celebrated 10 years since Azzalure®(AbobotulinumtoxinA) was first approved in Europe for the treatment of glabellar lines.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
The highly anticipated Aesthetics Media webinar, titled Azzalure (abobotulinum toxin type A) in Action: Key Principles and Treatment for Glabellar Lines in association with pharmaceutical company Galderma UK, is taking place on June 17 from 7pm. It will last approximately one hour.
On June 17 Aesthetics Media will be hosting its second webinar in association with pharmaceutical company Galderma UK.